Pharma Platform & Podcast

info@pharmavision.health

Launched in 2023, Pharma Vision is a groundbreaking initiative that caters to the global pharmaceutical community through two exceptional platforms: the Pharma Vision Podcast and an interactive online platform.

New FDA-Approved Medication for Migraine

The U.S. Food and Drug Administration (FDA) has approved Zavzpret (zavegepant) nasal spray for the acute treatment of migraine in adults.

Zavzpret is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray approved for this indication.

CGRP is a protein that plays a role in migraine attacks. Zavzpret works by blocking the activity of CGRP, which can help to reduce migraine pain and other symptoms.

In clinical trials, Zavzpret was shown to be effective in treating migraine. In one study, Zavzpret was found to be statistically superior to placebo in reducing pain and other migraine symptoms at two hours post-dose. It was also found to be well-tolerated, with the most common side effects being mild and transient.

The approval of Zavzpret provides patients with an additional treatment option for migraine. It can be used by adults who have tried other migraine medications and have not found them effective or who have not tolerated them well.

It is available by prescription only. The recommended dose is two sprays in one nostril. Zavzpret should not be used in patients who are allergic to zavegepant or any of the ingredients in Zavzpret.

Share this article
0
Share
Shareable URL
Prev Post

Role of AI in healthcare and the importance of oversight for AI healthcare tools

Next Post

Will 3D printed medicine be a game changer in the pharma world?

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to our newsletter
Get our recent podcasts and blogs